CompletedNCT04690556
Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD
PHASE3 · 600 planned enrolment
- Countries listed
- 7
- Registry update
- January 29, 2026
Registry Intervention View
Lucentis (ranibizumab)
Trial registrations containing the exact intervention label Lucentis (ranibizumab).
Exact registry label · Not reported
6 linked registrations
No aliases or equivalent products have been inferred.
Topics connected by trial metadata
2 linked registrations report posted results
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →Registered trials
CompletedNCT03150589
A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)
PHASE3 · 705 planned enrolment
- Countries listed
- 9
- Registry update
- May 21, 2021
CompletedNCT00500344
CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography
PHASE1 · 17 planned enrolment
- Countries listed
- 1
- Registry update
- May 3, 2018
CompletedNCT01269151
Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD
Phase not reported · 20 planned enrolment
- Countries listed
- 1
- Registry update
- April 8, 2015
CompletedNCT01638858
Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis)
Phase not reported · 25 planned enrolment
- Countries listed
- 1
- Registry update
- July 8, 2014
CompletedNCT00344227
Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)
PHASE2 · 40 planned enrolment
- Countries listed
- 1
- Registry update
- June 26, 2006